Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
232 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Osteoporosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2014', provides an overview of the Osteoporosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Osteoporosis Overview 10 Therapeutics Development 11 Pipeline Products for Osteoporosis - Overview 11 Pipeline Products for Osteoporosis - Comparative Analysis 12 Osteoporosis - Therapeutics under Development by Companies 13 Osteoporosis - Therapeutics under Investigation by Universities/Institutes 19 Osteoporosis - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Osteoporosis - Products under Development by Companies 24 Osteoporosis - Products under Investigation by Universities/Institutes 29 Osteoporosis - Companies Involved in Therapeutics Development 30 F. Hoffmann-La Roche Ltd. 30 Amgen Inc. 31 Daiichi Sankyo Company, Limited 32 Merck & Co., Inc. 33 Sumitomo Dainippon Pharma Co., Ltd. 34 Takeda Pharmaceutical Company Limited 35 Glide Pharmaceutical Technologies Limited 36 Novartis AG 37 Astellas Pharma Inc. 38 Chugai Pharmaceutical Co., Ltd. 39 Pfizer Inc. 40 Zydus Cadila Healthcare Limited 41 Biodel Inc. 42 Bone Medical Limited 43 Enzo Biochem, Inc. 44 Kaken Pharmaceutical Co., Ltd. 45 Lupin Limited 46 Medivir AB 47 Calzada Limited 48 Osteologix Holdings Plc. 49 NeoStem, Inc. 50 Dong Wha Pharma Co., Ltd. 51 PhytoHealth Corporation 52 Galapagos NV 53 Uni-Bio Science Group Ltd. 54 Oscotec Inc. 55 Dongkook Pharmaceutical Co., Ltd. 56 Merrion Pharmaceuticals Plc 57 Abiogen Pharma S.p.A. 58 Ventria Bioscience 59 Critical Pharmaceuticals Limited 60 Alkem Laboratories Ltd. 61 Amura Holdings Ltd. 62 IMMD Inc. 63 Alethia Biotherapeutics Inc. 64 Kedem Pharmaceuticals Inc. 65 Pantarhei Bioscience BV 66 Zealand Pharma A/S 67 Siena Biotech S.p.A. 68 Omeros Corporation 69 Radius Health, Inc. 70 EndoCeutics, Inc. 71 Ensoltek Co., Ltd. 72 TSRL, Inc. 73 Pfenex Inc. 74 Ausio Pharmaceuticals, LLC 75 Immunovo BV 76 ElexoPharm GmbH 77 Arcarios BV 78 Inbiopro Solutions Pvt. Ltd. 79 Lead Discovery Center GmbH 80 Wroclawskie Centrum Badan EIT+ Sp. z o.o. 81 Osteoporosis - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 87 Assessment by Route of Administration 90 Assessment by Molecule Type 92 Drug Profiles 95 denosumab - Drug Profile 95 bazedoxifene acetate - Drug Profile 98 romosozumab - Drug Profile 99 odanacatib - Drug Profile 101 zoledronic acid - Drug Profile 103 ibandronate sodium - Drug Profile 105 teriparatide - Drug Profile 107 neridronic acid - Drug Profile 108 (prasterone + acolbifene) - Drug Profile 109 (estrogen + progesterone) - Drug Profile 110 calcitonin - Drug Profile 112 PHN-031 - Drug Profile 114 teriparatide - Drug Profile 115 teriparatide - Drug Profile 117 alendronate sodium - Drug Profile 119 ES-1 - Drug Profile 121 PREOB - Drug Profile 122 AUS-131 - Drug Profile 123 IMD-2560 - Drug Profile 125 MIV-711 - Drug Profile 126 DW-1350 - Drug Profile 127 ZYPH-0907 - Drug Profile 129 OCT-1547 - Drug Profile 130 teriparatide - Drug Profile 131 CDRI-99/373 - Drug Profile 132 VEN-130 - Drug Profile 133 Oratonin - Drug Profile 134 teriparatide - Drug Profile 135 Recombinant salmon calcitonin - Drug Profile 136 AOD-9604 - Drug Profile 137 ZP-2307 - Drug Profile 139 MIV-710 - Drug Profile 140 MOR-106 - Drug Profile 141 Small Molecule to Agonize LRP for Osteoporosis - Drug Profile 142 AB-25E9 - Drug Profile 143 AM-3701 - Drug Profile 144 RAD-140 - Drug Profile 145 Sodium Quinate - Drug Profile 146 IBPB-008IG - Drug Profile 147 Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile 148 KDM-1103 - Drug Profile 149 PTH-CBD - Drug Profile 150 denosumab biosimilar - Drug Profile 151 TSG-6 - Drug Profile 152 S-101479 - Drug Profile 153 Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 154 Small Molecule to Inhibit 17Beta-HSD2 for Osteoporosis and Bone Fracture - Drug Profile 155 IPS-02 Series - Drug Profile 156 CH-5036249 - Drug Profile 157 alendronate sodium - Drug Profile 158 astrogorgiadiol - Drug Profile 159 parathyroid hormone biosimilar - Drug Profile 160 Compound-99-373 - Drug Profile 161 S-007-1500 - Drug Profile 162 Eu-232 - Drug Profile 163 AS-2690168 - Drug Profile 164 NEP-28 - Drug Profile 165 Small Molecules Targeting Androgen Receptor for Osteoporosis - Drug Profile 166 Biosimilar for Osteoporosis - Drug Profile 167 TAK-075 - Drug Profile 168 Small Molecule to target PTH-1R for Osteoporosis - Drug Profile 169 NBS-101 - Drug Profile 170 Drugs for Osteoporosis - Drug Profile 172 BN-005 - Drug Profile 173 BN-008 - Drug Profile 174 ODS-656 - Drug Profile 175 Monoclonal Antibody for Bone Diseases - Drug Profile 176 Recombinant Protein for Osteoporosis - Drug Profile 177 ARC-205 - Drug Profile 178 teriparatide - Drug Profile 179 VS-401 - Drug Profile 180 Vida-411 - Drug Profile 181 Peniel-3000 - Drug Profile 182 Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 183 Small Molecules for Osteoporosis - Drug Profile 184 Small Molecules for Osteopenia and Osteoporosis - Drug Profile 185 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 186 Proteins to Inhibit RANKL for Breast Cancer and Osteoporosis - Drug Profile 187 Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 188 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 189 Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 190 Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile 191 Drug for Osteoporosis - Drug Profile 192 Drug to Inhibit miR-31 for Osteoporosis - Drug Profile 193 genipin - Drug Profile 194 Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 195 Vaccine to Target Sclerostin for Osteoporosis - Drug Profile 196 Osteoporosis - Recent Pipeline Updates 197 Osteoporosis - Dormant Projects 211 Osteoporosis - Discontinued Products 217 Osteoporosis - Product Development Milestones 218 Featured News & Press Releases 218 Appendix 225 Methodology 225 Coverage 225 Secondary Research 225 Primary Research 225 Expert Panel Validation 225 Contact Us 226 Disclaimer 226
List of Tables Number of Products under Development for Osteoporosis, H2 2014 17 Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Development by Companies, H2 2014 (Contd..4) 24 Number of Products under Investigation by Universities/Institutes, H2 2014 25 Comparative Analysis by Late Stage Development, H2 2014 26 Comparative Analysis by Clinical Stage Development, H2 2014 27 Comparative Analysis by Early Stage Development, H2 2014 28 Comparative Analysis by Unknown Stage Development, H2 2014 29 Products under Development by Companies, H2 2014 30 Products under Development by Companies, H2 2014 (Contd..1) 31 Products under Development by Companies, H2 2014 (Contd..2) 32 Products under Development by Companies, H2 2014 (Contd..3) 33 Products under Development by Companies, H2 2014 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2014 35 Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 36 Osteoporosis - Pipeline by Amgen Inc., H2 2014 37 Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 38 Osteoporosis - Pipeline by Merck & Co., Inc., H2 2014 39 Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 40 Osteoporosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 41 Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2014 42 Osteoporosis - Pipeline by Novartis AG, H2 2014 43 Osteoporosis - Pipeline by Astellas Pharma Inc., H2 2014 44 Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 45 Osteoporosis - Pipeline by Pfizer Inc., H2 2014 46 Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 47 Osteoporosis - Pipeline by Biodel Inc., H2 2014 48 Osteoporosis - Pipeline by Bone Medical Limited, H2 2014 49 Osteoporosis - Pipeline by Enzo Biochem, Inc., H2 2014 50 Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 51 Osteoporosis - Pipeline by Lupin Limited, H2 2014 52 Osteoporosis - Pipeline by Medivir AB, H2 2014 53 Osteoporosis - Pipeline by Calzada Limited, H2 2014 54 Osteoporosis - Pipeline by Osteologix Holdings Plc., H2 2014 55 Osteoporosis - Pipeline by NeoStem, Inc., H2 2014 56 Osteoporosis - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014 57 Osteoporosis - Pipeline by PhytoHealth Corporation, H2 2014 58 Osteoporosis - Pipeline by Galapagos NV, H2 2014 59 Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H2 2014 60 Osteoporosis - Pipeline by Oscotec Inc., H2 2014 61 Osteoporosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 62 Osteoporosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 63 Osteoporosis - Pipeline by Abiogen Pharma S.p.A., H2 2014 64 Osteoporosis - Pipeline by Ventria Bioscience, H2 2014 65 Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H2 2014 66 Osteoporosis - Pipeline by Alkem Laboratories Ltd., H2 2014 67 Osteoporosis - Pipeline by Amura Holdings Ltd., H2 2014 68 Osteoporosis - Pipeline by IMMD Inc., H2 2014 69 Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H2 2014 70 Osteoporosis - Pipeline by Kedem Pharmaceuticals Inc., H2 2014 71 Osteoporosis - Pipeline by Pantarhei Bioscience BV, H2 2014 72 Osteoporosis - Pipeline by Zealand Pharma A/S, H2 2014 73 Osteoporosis - Pipeline by Siena Biotech S.p.A., H2 2014 74 Osteoporosis - Pipeline by Omeros Corporation, H2 2014 75 Osteoporosis - Pipeline by Radius Health, Inc., H2 2014 76 Osteoporosis - Pipeline by EndoCeutics, Inc., H2 2014 77 Osteoporosis - Pipeline by Ensoltek Co., Ltd., H2 2014 78 Osteoporosis - Pipeline by TSRL, Inc., H2 2014 79 Osteoporosis - Pipeline by Pfenex Inc., H2 2014 80 Osteoporosis - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 81 Osteoporosis - Pipeline by Immunovo BV, H2 2014 82 Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2014 83 Osteoporosis - Pipeline by Arcarios BV, H2 2014 84 Osteoporosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 85 Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2014 86 Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2014 87 Assessment by Monotherapy Products, H2 2014 88 Assessment by Combination Products, H2 2014 89 Number of Products by Stage and Target, H2 2014 92 Number of Products by Stage and Mechanism of Action, H2 2014 95 Number of Products by Stage and Route of Administration, H2 2014 97 Number of Products by Stage and Molecule Type, H2 2014 100 Osteoporosis Therapeutics - Recent Pipeline Updates, H2 2014 203 Osteoporosis - Dormant Projects, H2 2014 217 Osteoporosis - Dormant Projects (Contd..1), H2 2014 218 Osteoporosis - Dormant Projects (Contd..2), H2 2014 219 Osteoporosis - Dormant Projects (Contd..3), H2 2014 220 Osteoporosis - Dormant Projects (Contd..4), H2 2014 221 Osteoporosis - Dormant Projects (Contd..5), H2 2014 222 Osteoporosis - Discontinued Products, H2 2014 223
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
